Notícias e Atividades da Eagle Pharmaceuticals

Eagle Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Eagle Pharmaceuticals é uma empresa listada sob o símbolo EGRX (US).

Fusão, aquisição e financiamento envolvendo Eagle Pharmaceuticals.

• Revelation Pharma has announced the acquisition of Eagle Pharmaceuticals  (publicado em 24 de julho de 2023).

Veja o organograma con seus 9 executivos principais

Biografias mais buscadas da Eagle Pharmaceuticals

• Michael Graves, Interim Executive Chairman of the Board
• Robert Glenning, Director
• Richard Edlin, Director

Recentes movimentos de executivos em Eagle Pharmaceuticals

• Christopher Krawtschuk, ingressou na Companhia como Chief Financial Officer and Director  (Notícia publicada em 13 de novembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Eagle Pharmaceuticals.

Eagle Pharmaceuticals possui 1.824 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Roche (Suíça).

Popular M&A news in Farmacêutica

• Cyclo Therapeutics adquiriu Rafael Holdings (publicado em 28 de abril de 2025).
• Chimerix and Chimerix have merged  (publicado em 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Jean-Michel Demeure - Vice President, Finance Global Operations da Sanofi
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Eagle Pharmaceuticals

• Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation | Eagle Pharmaceuticals Investor Center
• Press Releases | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection) | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke | Eagle Pharmaceuticals Investor Center
• Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer | Eagle Pharmaceuticals Investor Center
• Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury | Eagle Pharmaceuticals Investor Center
• Press Releases | Eagle Pharmaceuticals Investor Center
• View more press releases Close

Redes sociais sobre Eagle Pharmaceuticals

• Eagle Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Eagle Pharmaceuticals na LinkedIn, Twitter e YouTube